Results 131 to 140 of about 12,163 (157)

Recombinant BCGs for tuberculosis and bladder cancer

Vaccine, 2021
Bacillus Calmette-Guérin (BCG) vaccine is an attenuated live strain of Mycobacterium bovis. It may be the most widely used vaccine in human history and is the only licensed human tuberculosis (TB) vaccine available. Despite its excellent safety history, a century of use in global vaccination programs, and its significant contribution to reducing TB ...
Alok K. Singh, Geetha Srikrishna, Trinity J. Bivalacqua, William R. Bishai   +3 more
openaire   +2 more sources

Recombinant BCG Vaccine Candidates

Current Molecular Medicine, 2007
Given the variable protective efficacy provided by Mycobacterium bovis BCG (Bacillus Calmette-Guérin), there is a concerted effort worldwide to develop better vaccines that could be used to reduce the burden of tuberculosis. Recombinant BCG (rBCG) are vaccine candidates that offer some potential in this area.
Rogelio, Hernàndez-Pando, Mauricio, Castañòn, Clara, Espitia, Yolanda, Lopez-Vidal   +3 more
openaire   +2 more sources

Improved protection by recombinant BCG

Microbes and Infection, 2005
Mycobacterium bovis bacille Calmette Guérin (BCG) is one of the most widely used live vaccines. Technologic advancement in genome manipulation enables the construction of recombinant BCG (rBCG) strains, which can be employed as highly immunogenic vaccines against tuberculosis with improved safety profile.
Nasser Eddine, A., Kaufmann, S.
openaire   +3 more sources

Recombinant BCG therapy suppresses melanoma tumor growth

Annals of Surgical Oncology, 1995
Melanoma is the fastest rising cancer in the United States. Bacillus Calmette-Guerin (BCG) has been genetically engineered to actively express and secrete the cytokine interleukin-2 (IL-2). Both BCG and IL-2 have known potent antitumor and immunomodulatory properties.This recombinant BCG (rBCG 3A) has been tested as an intratumoral injection and a ...
R B, Duda, H, Yang, D D, Dooley, G, Abu-Jawdeh   +3 more
openaire   +2 more sources

Recombinant BCG as a candidate oral vaccine vector

Research in Microbiology, 1990
Bacille Calmette-Guerin (BCG), currently the most widely used vaccine in the world, was originally administered for many years as an oral vaccine. The low frequency of serious complications, inexpensive production, and adjuvanticity make BCG an ideal candidate for a recombinant vaccine vehicle.
R G, Barletta, B, Snapper, J D, Cirillo, N D, Connell, D D, Kim, W R, Jacobs, B R, Bloom   +6 more
openaire   +2 more sources

Development of BCG As a Recombinant Vaccine Vehicle

1990
The bacille Calmette-Guerin (BCG) was developed by Dr A. Calmette and his associate Dr. C. Guerin at the Pasteur Institute in the early years of this century as a vaccine against tuberculosis. Despite enormous efforts by large numbers of experimental microbiologists of the time, the general methods for attenuating viruses and developing vaccines ...
W R, Jacobs, S B, Snapper, L, Lugosi, B R, Bloom   +3 more
openaire   +2 more sources

Mycobacterium bovis BCG moreau is naturally deficient in homologous recombination

Tuberculosis, 2020
The ability to perform genetic manipulation of mycobacteria is important for characterization of gene function. Homologous recombination-based protocols are frequently used for reverse genetics studies with mycobacteria. It is known that Mycobacteriumbovis BCG Russia, closely related to M. bovis BCG Moreau, is a natural recA deficient strain and is non-
Schwarz, Marcos Gustavo Araujo, Corrêa, Paloma Rezende, Malaga, Wladimir, Guilhot, Christophe, Mendonça-Lima, Leila   +4 more
openaire   +3 more sources